Transsulfuration Reprogramming: A Metabolic Driver of BRAF‐V600E Resistance in Melanoma

Transsulfuration Reprogramming: A Metabolic Driver of BRAF‐V600E Resistance in Melanoma

Saved in:

Bibliographic Details
Main Authors:	Juntong Chen, Guoqing Ding, Jie Zhang
Format:	Article
Language:	English
Published:	Wiley 2025-06-01
Series:	MedComm – Future Medicine
Online Access:	https://doi.org/10.1002/mef2.70024
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Comparative effectiveness among BRAF plus MEK inhibitors for patients with BRAF V600-mutant melanoma☆
by: G.K. In, et al.
Published: (2024-12-01)

COP1 Deficiency in BRAF<sup>V600E</sup> Melanomas Confers Resistance to Inhibitors of the MAPK Pathway
by: Ada Ndoja, et al.
Published: (2025-06-01)

Reflectance confocal microscopy features of BRAF V600E mutated thin melanomas detected by immunohistochemistry.
by: Ana Claudia Urvanegia, et al.
Published: (2017-01-01)

Novel therapy: Combined BRAF and MEK inhibitors for locally advanced BRAF V600L–Positive mucosal melanoma in hypopharynx
by: Sivakamavalli Jeyachandran
Published: (2024-06-01)

High BRAF V600 Mutation Level Associated with Worse Outcome in Metastatic Melanoma Patients Receiving BRAF and MEK Inhibitors
by: Ariane Fizazi, et al.
Published: (2024-11-01)

Loss of the chromatin modifier Kdm2aa causes BrafV600E-independent spontaneous melanoma in zebrafish.
by: Catherine M Scahill, et al.
Published: (2017-08-01)

Cross-method comparison for BRAF p.V600 mutation cfDNA testing in Melanoma: BRAFI study
by: Clara Mayo de las Casas, et al.
Published: (2025-01-01)

A methyl-to-acetyl switch in H3K27 drives metabolic reprogramming and resistance to BRAFV600E inhibition in melanoma
by: Jiang Zhou, et al.
Published: (2025-10-01)

Antitumor effects of immunotherapy combined with BRAF and MEK inhibitors in BRAF V600E metastatic colorectal cancer
by: Eunyoung Tak, et al.
Published: (2025-03-01)

Determination of BRAF V600E (VE1) protein expression and BRAF gene mutation status in codon 600 in borderline and low-grade ovarian cancers
by: Pawel Sadlecki, et al.
Published: (2017-05-01)

Prospects of BRAF/MEK Inhibitor Therapy in Papillary Craniopharyngiomas with the BRAF V600E Mutation: A Scoping Review
by: Shingo FUJIO, et al.
Published: (2025-05-01)

Correction: Antitumor effects of immunotherapy combined with BRAF and MEK inhibitors in BRAF V600E metastatic colorectal cancer
by: Eunyoung Tak, et al.
Published: (2025-04-01)

Use of BRAF V600E as a Molecular Marker in Aggressive Colorectal Cancer
by: Bethy S Hernowo, et al.
Published: (2016-05-01)

Use of BRAF V600E as a Molecular Marker in Aggressive Colorectal Cancer
by: Bethy S Hernowo, et al.
Published: (2016-05-01)

Surrogate to predict overall survival in patients with BRAF V600E-mutant colorectal cancer treated with BRAF inhibitor combinations
by: J. Ros, et al.
Published: (2025-09-01)

THE ROLE OF BRAF V600E IN THE DEVELOPMENT OF THYROID CANCER PHENOTYPE: A SYSTEMATIC REVIEW
by: Pratia Mega, et al.
Published: (2025-01-01)

A multi-center cross-sectional investigation of BRAF V600E mutation in Ameloblastoma
by: Khin Mya Tun, et al.
Published: (2025-04-01)

Frequent mutation of K-RAS in addition to BRAF V600E in Ameloblastoma – An immunohistochemical study
by: Aishwariya Mohanty, et al.
Published: (2024-06-01)

BRAF V600E Mutation in Odontogenic Keratocyst: A Systematic Review and Meta-Analysis
by: Jéssica da Silva Cunha, et al.
Published: (2025-01-01)

Investigating therapeutic efficacy of dacarbazine and temozolomide, alone and in combination with BRAF(V600E) siRNA in A375 human melanoma cell line
by: Fatemeh Tabandeh, et al.
Published: (2025-06-01)

Immunohistochemical Analysis of BRAF (V600E) Mutation and P16 Expression in Malignant Melanoma in Lagos, Nigeria: A 10-Year Retrospective Study
by: O. Obadofin, et al.
Published: (2019-01-01)

Adjuvant anti-PD-1 therapy improves melanoma-specific survival in stage IIIC-IV melanoma patients with high tumor mutation burden and BRAF V600 mutation
by: Julia Forschner, et al.
Published: (2025-08-01)

BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance
by: Ryan J. Sullivan, et al.
Published: (2011-01-01)

Metabolic parameters on baseline and early [18F]FDG PET/CT as a predictive biomarker for resistance to BRAF/MEK inhibition in advanced cutaneous BRAFV600-mutated melanoma
by: Bernies van der Hiel, et al.
Published: (2025-05-01)

Can mutation abundance assess the biological behavior of BRAF V600E-positive papillary thyroid carcinoma?
by: Yeqin Ni, et al.
Published: (2025-07-01)

Metabolic reprogramming in melanoma therapy
by: Dongliang Shen, et al.
Published: (2025-07-01)

BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm
by: Jennifer A. Silver, et al.
Published: (2021-11-01)

Postpartum colonic squamous cell carcinoma with a BRAF V600E mutation: a case report
by: Qin Wang, et al.
Published: (2025-08-01)

BRAF V600E-mutant colorectal cancer with CNS metastases treated successfully with encorafenib, binimetinib and cetuximab
by: Toru Imai, et al.
Published: (2024-12-01)

BRAF V600E-mutated lung adenocarcinoma with thyroid metastasis as the initial manifestation: a case report
by: Yufei Liu, et al.
Published: (2025-02-01)

Comparision Of BRAF V600E, COX–2 and p53 As Biomarkers For The Early Detection Of Colorectal Cancer
by: Hina Wasti, et al.
Published: (2019-06-01)

Evolution of Acquired Drug Resistance in BRAF-Mutant Melanoma
by: Josué Ballesteros-Álvarez, et al.
Published: (2024-10-01)

Cost-effectiveness analysis of encorafenib and binimetinib combination as first-line treatment for metastatic or unresectable <i>BRAF</i> V600-mutated metastatic melanoma in Russia
by: N. A. Avxentyev, et al.
Published: (2023-11-01)

TREATMENT OF <em>BRAF</em><sup>V600E</sup> POSITIVE ANAPLASTIC THYROID CARCINOMA: CASE REPORT
by: P. A. Nikiforovich, et al.
Published: (2020-10-01)

Cyclin-dependent kinase 1 targeting improves sensitivity to radiation in BRAF V600E colorectal carcinoma cells
by: Girolamo Spagnoletti, et al.
Published: (2018-04-01)

The prevalence of BRAF V600E mutation in hairy cell leukemia: A systematic review and meta-analysis study
by: Mehrdad Payandeh, et al.
Published: (2019-01-01)

Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation
by: Takuji Seo, et al.
Published: (2020-01-01)

BRAF V600E and Pten deletion in mice produces a histiocytic disorder with features of Langerhans cell histiocytosis.
by: David S Nelson, et al.
Published: (2019-01-01)

Relationship between the BRAF V600E and tumor size, lymph node, and distant metastasis in papillary thyroid carcinoma
by: Edmond Rukmana Wikanta, et al.
Published: (2022-06-01)

Targeting Non-V600 Mutations in BRAF: A Single Institution Retrospective Analysis and Review of the Literature
by: Hirra A. Chaudhary, et al.
Published: (2024-08-01)